EGFR and adenocarcinoma: The negative results of SCOPE1 may be partly due to the absence of incorporating biomarker-driven anti-EGFR therapy with definitive chemoradiotherapy.47 In addition, the study enrolled patients with a mixture of squamous cell cancer and adenocarcinoma, which may lead to the benefits of cetuximab in combination with CRT being underestimated.